The Impact of Social Proximity on Conversion to Generic Prescription Medications
調査の概要
状態
詳細な説明
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication. The testimonial treatment arm will receive the exact same letter, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial. The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Missouri
-
St. Louis、Missouri、アメリカ、63121
- Express Scripts
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Employee of a company that uses Express Scripts as its pharmacy benefits manager.
- Employee at a company with predominantly union employees.
- Currently taking a brand name medication with an exact generic equivalent.
Exclusion Criteria:
- Employees on any psychological prescription medication.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：ヘルスサービス研究
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Testimonial and Union Arm
The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
|
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
|
|
実験的：Control
The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication.
|
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
|
|
実験的：Testimonial Treatment Arm
The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial.
|
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Conversion from Brand Name to Generic Prescription Medication
時間枠：One month to one year after the intervention.
|
We will measure conversion rates of employees from brand name to generic prescription medication by treatment arm.
|
One month to one year after the intervention.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Union Status and Conversation to Generic Medication
時間枠：One month to one year after the intervention.
|
We will see how union affiliation affects the employee conversion rates from brand name to prescription medication by treatment arm.
|
One month to one year after the intervention.
|
協力者と研究者
捜査官
- 主任研究者：David Laibson, Ph.D、National Bureau of Economic Research
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 0002
- P30AG034532 (米国 NIH グラント/契約)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。